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Abstract
Background and aim: According to ACR 2011 criteria, Fibromyalgia Syndrome (FMS) is a disorder
characterized by widespread musculoskeletal pain for more than 3 months accompanied by fatigue, sleep, memory
and mood issues.
Recent reviews show that Mind Body Therapies (MBT) are effective to reduce the majority of FMS symptoms.
Rességuier Method (RM) is a MBT that aims to obtain patient nonjudgmental awareness and control of bodily
perceptions, which is effective in reducing physical and mental disorders in many rheumatic diseases. The aim of
this pilot study is to evaluate the effects of RM on FMS clinical and clinimetric parameters and on neuromuscular
hyper excitability (NMH), defined as reduction in the excitability threshold assessed by ischemia-hyperpnea test
(IHT).
Patients and methods: Fifty-nine patients (pts), 54 women and 5 men, age 50.33 ± 12.15, were treated with RM,
1 hour once a week for 8 weeks.
At baseline (T0) and at the end of RM treatment (T1) they were evaluated for NMH by IHT. According to IHT
results, pts were considered as negative or positive. They were also assessed for pain (Numeric Rating Scale –
NRS; Pain and Regional Pain Scale–RPS), disability (Fibromyalgia Impact Questionnaire –FIQ and Health
Assessment Questionnaire-HAQ), health related quality of life (SF-36) mood disorders (Hospital Anxiety and
Depression Scale-HADS), sleep quality (NRS Sleep) and fatigue (Functional Assessment of Chronic Illness
Therapy–fatigue: FACIT-f).
Results: At baseline, IHT was negative in 7 (11.86%) FMS pts and positive in 52 (88.14%), while after RM
treatment it resulted negative in 28 (47.46%) pts and positive in 31 (52.54%). Our results show significant
improvement for pain, RPS, FIQ, HAQ, HADS, sleep quality, FACIT-f, SF_36 Summary Mental Index (SMI) and
Summary Physical Index (SPI) (p<0.01 for all the items).
Conclusions: We found a high prevalence of NMH in FMS patients, as assessed by IHT. We confirmed the
efficacy of RMon clinimetric measures of FMS symptoms. Moreover, we showed the RM efficacy on NMH that,
according to our results, could be considered as one of the therapeutic targets in FMS chronic pain.
Keywords: Fibromyalgia Syndrome (FMS); Ischemia-Hyperpnea
Test (IHT); Electromyography(EMG); Quality of Life (QoL);
Rességuier Method (RM); Mind Body Therapies (MBT); Health
Related Quality of Life (HRQoL)
Introduction
Fibromyalgia Syndrome (FMS) is a condition characterized by
chronic widespread pain for more than 3 months and other symptoms
such as fatigue, non-restorative sleep, cognitive and somatic symptoms
(headache, depressive symptoms, and irritable bowel) [1]. FMS impairs
Quality of Life (QoL), social life, working activities and implies mood
disorders, such as anxiety and depressive symptoms [2].
As other conditions characterized by chronic pain, FMS represents a
huge burden that traditional Western medicine is currently failing to
approach efficaciously. Despite many investigation of a wide range of
pharmacological and non-pharmacological options, an optimal
management of FMS is still unclear [3-5].
The relevance of Mind Body Therapies (MBT) in FMS is supported
by recent studies that attribute the pathophysiology of the disease to
central sensitization that may explain the different symptoms. FMS, in
fact, was recently included in Central Sensitivity Syndromes
conditions, characterized by a state of hyper excitement of the central
nervous system, due to an amplification of peripheral nociceptive
input, that leads to pain exacerbation and excessive sensitivity to
peripheral noxious and non-noxious stimuli [6,7].
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According to these recent findings, treatment of FMS should target
Central Sensitivity changes with centrally acting drugs and with
centrally acting non-pharmacological therapies e.g. MBT [7]. Many
studies, in fact, showed the efficacy of MBT in approaching the
cardinal symptoms of FMS, such as chronic pain, fatigue, difficulty in
sleeping and relaxing, depression, anxiety and psychological distress,
and thereby, in improving activities of daily living, self-efficacy, Quality
of Life (QoL) and finally in reducing disability [6].
Rességuier Method (RM) is a MBT, tailored to patient’s features,
that aims to obtain patient nonjudgmental awareness and control of
bodily perceptions thus reaching a modulation of responses to pain.
RM is based on the continuous attention of the therapist to the patient
during all the session. This particular attitude is called “accompanying
posture”. In a previous study, we showed RM leading to a significant
improvement of QoL, relaxation, sleep and also to a decrease of
disability and perceived pain in FMS patients, thus reducing the uptake
of analgesics [8].
As musculoskeletal pain is a cardinal symptom of FMS,
electromyography (EMG) was used in muscle evaluation: EMG
changes were observed both in involved and uninvolved skeletal
muscles [9,10].
EMG and, above all, ischaemia-hyperpnea test (IHT), may detect
neuromuscular hyper excitability (NMH), defined as a reduction in the
excitability threshold, that may be nonspecific or related to tetany
[11,12].
Vitali et al. demonstrated a higher prevalence of NMH, assessed
with IHT, in FMS in comparison with rheumatoid arthritis. Bazzichi et
al. reported 25.8% of IHT positive patients in FMS also presenting a
higher incidence of depressive and panic disorders and a lower number
of tender points than in IHT negative patients [13,14].
A recent study of our group demonstrated that 62.5% of 145
patients suffering from FMS were positive to IHT. Moreover, IHT
positive patients had a lower Health Related Quality of Life (HRQoL)
and a higher fatigue than IHT negative patients [15]. Thus, IHT
positivity seemed to identify FMS patients with a more severe disease.
The principal aim of the present pilot study was to evaluate the
effect of RM treatment on NMH, assessed by IHT [8].
Thus, the aims of the study were to evaluate:
• the prevalence of NMH, assessed by IHT in FMS patients;
• the effects of RM on NMH, assessed by IHT;
• the efficacy of RM on clinical and clinimetric parameters in order
to confirm its utility as a tailored treatment on FMS patients.
Patients and Methods
Eighty FMS patients, 8 men and 72 women, were recruited,
consecutively from January 2015 to June 2015, from the outpatient
clinic of the Division of Rheumatology, Department of Experimental
and Clinical Medicine, University of Florence.
Inclusion criterion was the diagnosis of FMS according to the
American College of Rheumatology [1].
Exclusion criteria were changes in thyroid function (Free
triiodothyronine (FT3), free thyroxine (FT4), Thyroid-stimulating
hormone (TSH), Thyroperoxidase antibodies (TPOAb), thyroglobulin
antibodies (TgAb) and TSHAb receptor (TRAb)), electrolytes
((Magnesium (Mg) and Potassium (K)), Calcium (Ca), Parathyroid
hormone (PTH) and 25-OH vitamin D3.
Patients recruited signed a written informed consent for all the
procedures. All the procedures were in accordance with Helsinki
Declaration of 1975/83 and the study was approved by local Ethical
Committee.
At baseline (T0), patients were evaluated for demographic
characteristics (sex, age) and disease duration. All patients were tested
by standard EMG and IHT to evaluate neuromuscular
hyperexcitability. They performed RM treatment, 1 hour once a week
for 8 weeks, with the same physiotherapist (CDF). They continued
their pharmacological treatments (antidepressant agents by 13 pts,
anxiolytic medications by 15 pts, anticonvulsant drugs by 5 pts and
land exercise was continued by 4 pts, NSAIDs and analgesics only as
needed) and throughout the period of the study they were asked not to
start any new pharmacological therapy.
Patients were assessed by clinic and clinimetric tools at T0 and at
the end of the study (T1) for pain, sleep, disability, fatigue, QoL and
mood disorders.
Assessment
Electromyography (EMG) and Ischaemia-hyperpnea test
(IHT)
EMG assesses the electrical potential formed in a muscle during its
contraction (motor unit action potential (MUAP)), which reflects the
activity of a group of motor units.
EMG/NCS and IHT were performed with Synergy
electromyography equipment (VIASYS Health Care UK, Manor Way,
Old Woking, Surrey, GU22 9JU, UK, 2007) by using surface electrodes
for NCS and coaxial needles for EMG and IHT.
For IHT a coaxial needle was inserted in the first dorsal interosseous
dorsal muscle of the left hand. The examination consisted of 2 phases:
1. 1. Ischaemia phase (5 minutes), caused by applying the cuff of the
sphygmomanometer (blood pressure cuff) to the lower third of
the arm with a pressure of 200 mgHg.
2. 2. Hyperpnea phase (3 minutes), immediately after ischaemia,
executed by inviting the patient to perform a deep
hyperventilation with a frequency of around 40 breaths a minute.
In normal subjects, no spontaneous activity is present in the
muscle at rest and during IHT (Figure 1a).
The fasciculation potential, a spontaneous involuntary discharge of
an individual motor unit, may be defined as singlet. Spontaneous
MUAPs that fire in groups of 2, 3, or multiple potentials are known as
doublets, triplets, and multiplets, respectively. These potentials and the
singlets, often seen together, represent the spontaneous depolarization
of a motor unit or of its axon.
We considered IHT as positive only after the observation of coupled
discharges (doublets, triplets or multiplets) (Figure 1b) [16]. The carpal
spasm (tetany), which can be observed in the hands of some patients
during ischaemia hase, is not supported by repetitive discharges
(multiplets), but by EMG, activity (sub-interferential pattern) similar
to that observed during voluntary recruitment. When doublets, triplets
and multiplets are not associated to carpal spasms or tetany, the
condition is defined as not specific NMH.
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Figure 1a: Negative IHT: absence of spontaneous activity during the
test (presence of only isolate motor action potential).
Figure 1b: Positive IHT: presence of double, triple or multiple
discharge (two, three or more motor action potentials of the same
form and nearly the same amplitude).
Clinimetric assessment
Anxiety and depression were assessed by Hospital Anxiety and
Depression Scale (HADS). It is a reliable and valid self-report
questionnaire for identifying and quantifying psychological distress
[17]. It consists of two subscales: HADS-A (anxiety) and HADS-D
(depression). HADS includes seven questions for each dimension,
whose scores ranges from 0 (no depression, no anxiety) to 21 (maximal
depression or anxiety). Evaluation was based on cut-off score >8 in
both subscales [18].
Pain was rated with an auto-administered Number Rating Scale
(NRS 0-10), which measures current pain intensity on a 0-10 scale
(0=no pain, 10=worst pain) [19].
Regional pain scale (RPS) is a measure of the number of painful
body regions [20].
Sleep quality was assessed by Number Rating Scale (NRS 0-10),
used to measure the quality of sleep reported last week (0=the worst
perceived sleep and 10=the best-perceived sleep).
Disability: Fibromyalgia Impact Questionnaire (FIQ) and Health
Assessment Questionnaire (HAQ) were used to assess disability. The
first is a specific self-administered instrument designed to evaluate the
overall impact of FMS over many dimensions (physical functioning,
work status, depression, anxiety, sleep, pain, stiffness, fatigue, and well-
being). It consists of 10-items and it is scored between 0 and 100, with
higher scores representing higher disability [21,22].
HAQ is a self-report questionnaire referring to global disability,
rated from 0 (no difficulty) to 3 (unable to do) [23].
Fatigue was evaluated by Functional Assessment of Chronic Illness
Therapy-Fatigue (FACIT-F) that assesses physical and functional
consequences of fatigue in performing activities of daily living. Total
score ranges 0-52, high scores representing less fatigue [24].
Health related quality of life (HRQoL), was assessed by Italian
version of Medical Outcomes Survey Short Form 36 (SF-36) which is a
self-report questionnaire with 36 items organized into 8 domains then
combined into summary physical index (SPI) and summary mental
index (SMI). For all the scales, the score is 0-100, with higher scores
corresponding to better and lower scores to worse HRQoL (range 0–
100) [25].
Rehabilitation
Rességuier Method (RM)
RM is a MBT that aims to obtain patient nonjudgmental awareness
and control of bodily perceptions, in particular nociception. Its
mainstay is the therapeutic relationship between therapist and patient,
based on the continuous attention to the patient during all the session
(regarded as “accompanying posture”). During the individual session,
the therapist maintains and continuously monitors the state of
attention and awareness of the patient by verbal and manual contacts
leading to perform bodily active and conscious movements and
respiratory exercises always respectful of the pain threshold and
tailored for the patients in different positions (supine, sitting and
standing) [26,27].
The purpose of the session is to obtain patient awareness and
control of perceptions, derived from individual parts of the body. This
may allow the patient to modulate the response to pain perception. The
capacity to perceive the body and to regulate the sensations and the
emotion is obtained by the instruments of RM as follows:
1. 1. Verbal contact of the therapist. The therapist asks the patient
about her/his perception of specific body segments, particularly
of painful areas. Guided by the therapist, the patient describes the
perceived characteristics of these areas in terms of dimensions,
weight, consistency and symmetry.
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2. 2. Manual contacts of the therapist on the patient, essential to
promote patient perception of specific areas.
3. 3. “Petite gymnastique”, consisting of exercises performed during
the sessions:
• Exercises of conscious respiration;
• Active and conscious movements of head, trunk, upper and lower
limbs, firstly in a supine position, then sitting and standing. The
therapist chooses the appropriate movements and exercises,
tailoring them to the patient.
1. 4. Home exercises, consisting of the movements of “Petite
gymnastique” chosen by the therapist and tailored on the patient,
are performed daily (30 minutes/day) both during the treatment
period, and during follow-up.
Data analysis
Statistical analysis: Data are presented as Mean ± Standard
Deviations (M ± SD) for continuous variables and as numbers and
percentages for binomial variables. Continuous variables were tested
with the Kolmogorov–Smirnov test for normality.
Due to normal distribution of the data, student’s T-test for repeated
measures was used to compare variables at baseline (T0) and after RM
(T1), in order to detect effect of the treatment (SPSS statistical package,
version 20.0 for Windows, SPSS, Chicago, USA). The differences were
considered significant for P <0.05 (IC=95%).
Minimal clinically important difference (MCID): We used MCID in
order to quantify if an individual patient within a particular treatment
group has a clinically significant response and if it can be used to assess
the mean percentage change within a particular treatment group.
MCID accounts for the varying baseline levels of functional
impairment [28]. The analysis indicates that a >14% change in the FIQ
total score is clinically relevant, and results of these analyses should
enhance the clinical utility of the FIQ in research and practice [29]. A
reduction in HAQ of >0.25 from baseline was used to determine the
proportion of patients with improvements in HAQ that met or
exceeded the MCID at each time point [30].
Results
Eighty FMS patients were enrolled: 21 of them did not perform IHT
after RM. 21 of them did not complete the ischaemia/hyperpnea
testing. 11 of them felt better and refused to continue the study, 6 of
them did not finished RM treatment and 4 of them refused to perform
IHT. Therefore, 21 patients were excluded from the study. Thus, we
assessed 59 FMS patients (54 women and 5 men; mean age: 50.33 ±
12.15 years; 9.51 ± 10.43 disease duration).
Prevalence of IHT in FMS patients at baseline and after RM
treatment
At T0, 7 (11.86%) patients were negative and 52 (88.14%) were
positive while after the RM treatment 28 (47.46%) patients were
negative and 31 (52.54%) were positive.
The 28 patients with negative IHT at T1 consisted in 4 patients
negative also at T0 and 24 patients previously positive. The 31 patients
with positive IHT at T1 were in 28 patients already positive at T0 and 3
previously negative patients.
Comparison of clinimetric parameters before and after MR
treatment
The results shows a statistically significant improvement (p<0.05) by
comparing HADS A, HADS D, HADS TOT, Sleep Quality, Pain
Intensity, HAQ, FACIT-f, FIQ, SF_36 SMI and RPS data at baseline
(T0) with T1 (p<0.001 for all comparisons). Also SF_36 SPI improved
significantly (p<0.01) (Table 1). In addition, disability, assessed by
HAQ and FIQ, improved in FMS patients after MR treatment
according to MCID (minimal clinically important difference). More
than 58% of the patients reported a clinically significant improvement
in HAQ and more than 82% improved according to FIQ.
 T0 T1 P
Clinimetric
Parameter
Media ±DS Media ±DS
HADS-A 10.93 ± 4.76 7.74 ± 4.26 <0.001
HADS-D 9.13 ± 5.0 5.56 ± 3.68 <0.001
HADS-TOT 20.05 ± 8.69 13.62 ± 6.94 <0.001
Sleep Quality 4.17 ± 2.147 6.65 ± 2.13 <0.001
Pain 5.71 ± 2.71 3.06 ± 2.7 <0.001
FIQ 57.46 ± 18,1 29.83 ± 19.59 <0.001
HAQ 0.84 ± 0.71 0.33 ± 0.59 <0.001
FACIT 23.57 ± 10.66 13.66 ± 9.29 <0.001
SF-36 SMI 35.33 ± 12.4 44.21 ± 9.9 <0.001
SF-36 SPI 35.64 ± 11.4 42.36 ± 10.46 <0.01
RPS 12.9 ± 4.74 6.56 ± 6.025 <0.001
Table 1: HADS A (Hospital Anxiety and Depression Scale Anxiety),
HADS D (Hospital Anxiety and Depression Scale Depression), HADS
TOT (Hospital Anxiety and Depression Scale Total score), FIQ
(Fibromyalgia Impact Questionnaire), HAQ (Health Assessment
Questionnaire), FACIT-f (Functional Assessment Chronic Illness
Fatigue), SF_36 SMI (SF36 Summary Mental Index); SF36 SPI (SF_36
Summary Physical Index), RPS (Regional Pain Scale).
Discussion
The results of this study showed that 88.14% of our FMS patients
were positive to IHT, demonstrating a high prevalence of NMH.
As all subjects (positive and negative to IHT) presented normal
calcium metabolism, NMH was not linked to hypocalcaemia and/or
hypoparathyroidism.
On the basis of bioptic, metabolic, and molecular studies, muscles
are considered as involved in FMS. Muscle changes may initiate or
perpetuate sensitization of muscle nociceptors and provide a tonic
afferent input to central nervous system (CNS) that ultimately leads to
central sensitization.
EMG, used in different studies to evaluate muscular
physiopathology in FMS, showed altered muscle fibres conduction
velocity (CV) in involved muscles [9] and high muscle membrane CV
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in muscles not clinically involved in FMS [24], suggesting an overall
muscular membrane disorder [10,25].
IHT may detect NMH, defined as a reduction in the threshold of
excitability of skeletal muscles [11,12]. only two studies analyzed NMH
in FMS by IHT. Vitali et al. showed a higher prevalence of NMH in
FMS in comparison with Rheumatoid Arthritis [13], while Bazzichi et
al. [14] diagnosed spasmophilia as a comorbid and distinct condition
in 25.8% of FMS patients. In this study, the diagnosis of spasmophilia
was based on the positive results of IHT and on the presence of at least
1/4 of the following clinical symptoms: cramps and/or tetanic seizures,
paraesthesia, tachycardia and/or dyspnea, asthenia, and dizziness.
However, as Wolfe et al. included in 2010 diagnostic ACR criteria
paraesthesia, muscle stiffness and contractures, cramps, seizures or
convulsions, tachycardia, dyspnoea, asthenia and dizziness, in our
opinion, these symptoms could be part of the wide array of FMS
manifestations rather than being representative of spasmophilia [31].
NMH, as defined by positivity at IHT, is present in the majority
(88.14%) of our group of FMS patients. The reason of IHT positivity in
patients with FMS is not known.
FMS is characterized by excessive sensitivity to many stimuli
including pressure, chemicals and ischemia. Thus, it can be assumed
that ischemia and hyperpnea, during the IHT, cause a progressive
increase of activation in the second order neurons, projecting to the
brain. This mechanism produces the hyperexcitable state within the
CNS by involving finally ventral horn neurons that can produce
discharge of doublets, triplets and multiplets [6].
Moreover, in our FMS patients IHT positivity always begins in the
hyperpnea phase which causes also a high degree of psychological
distress in the majority of FMS patients. It is known that psychological
distress increase central sensitization and the subsequent increased
motor activity [32].
The diagnosis of FMS is still difficult, underestimated and often
delayed [33]; therefore, an easily performed and reproducible test, able
to confirm or facilitate the diagnosis, is needed. Our results suggest
that NMH is common in patients with FMS and that IHT could be
helpful in diagnosing and also in characterizing FMS. In a previous
study of ours, in fact, NMH positivity identified patients, in which
FMS symptoms caused a higher distress, leading to QoL impairment
and to increased fatigue [15]. Then IHT positivity may also be useful in
better tailoring treatment interventions, particularly non
pharmacological treatments such as MBT, dealing efficaciously with
pain, depression, anxiety, psychological distress, fatigue and QoL [34].
In our sample, in fact, at baseline approximately 11% were negative at
IHT, then after RM treatment 46% of positive patients turn into
negative.
Moreover, in agreement with the literature, our FMS patients
demonstrated at baseline, impaired HRQOL, disability, fatigue and
pain, while after MR treatment, at T1, patients significantly improved
in Mood, Sleep Quality, Pain, Disability, Fatigue, HRQOL in respect to
T0 [15].
The relevance of centrally acting non-pharmacological therapies e.g.
MBT in FMS is supported by recent studies that attribute the disease to
central sensitization that explains all symptoms of FMS [7]. About this,
many reviews report positive results of MBT and cognitive behavioral
therapies in inducing a long lasting improvement of the key symptoms
of FMS [4,33].
According to literature, MBT seem to be suitable and efficacious in
FMS patients, by acting both on somatic and on central-derived
symptoms; these methods that integrate physical, psychological,
emotional, spiritual and behavioral elements, promote the rebalancing
of the mind and body, often impaired in these patients. MBT, such as
Tai Chi, Yoga and Qi Gong are strongly recommended by the German
guidelines [35]. Tai Chi is proved safe and efficacious in FMS patients
in which it reduces sleep disorders, psychological distress and fatigue
and improves QoL [4,33,36,37]. In FMS, Qi Gong is effective and
useful in improving local tenderness (tender points), pain, disability,
psychological health and HRQoL [4,38-40]. Mindfulness Based Stress
Reduction program may help in coping with stress and in improving
mood and disability, while interventions based on different Yoga
programs improved disability, pain, fatigue, mood and coping
strategies [4,41].
In our study, the significant improvement of all the clinimetric
parameters suggests a positive effect of RM in the treatment of FMS
patients.
In contrast with techniques directly inducing relaxation, and
somewhat similarly to Mindfulness Meditation, RM promotes a
nonjudgmental awareness to sensations and emotions as they arise
that, in turn, induces self-observation and thoughtful responses to
pain.
Acting on these mechanisms, RM in FMS breaks the vicious circle
of chronic pain-stress typical of the disease, and may lead to a more
attentive vision on the immediate experience.
In a previous study [8], we assessed the efficacy of RM, in the
treatment of FMS patients; the results showed a significant
improvement of QoL, a significant decrease of disability and perceived
pain in patients with reduction of the analgesics uptake. It is important
to note that the benefits achieved during the treatment are maintained
at follow-up.
These results were confirmed also in another study [42], in which an
integrated treatment with RM and Qi Gong in FMS patients led to a
significant improvement in pain, disability, quality of life, tenderness,
anxiety. RM also ameliorated sleep and QG improved depression.
Furthermore, in the present study, a significant improvement of
disability is also confirmed by the MCID values for HAQ and FIQ.
58.54% of FMS patients showed a clinically significant improvement
according to HAQ score, and more than 80% showed a significant
reduction of disability according to FIQ score (which is a specific tool
in FMS).
RM, as other MBT, in FMS patients help to cope with pain and to
disconnect the affective response to pain, thus decreasing pain
catastrophizing and the consequent emotional distress.
It can therefore be assumed that RM influence IHT results in FMS
patients by reducing psychological factors that contribute to central
sensitization. Gracely et al. found that catastrophic thoughts in FMS
are associated also with increased activity in several motor brain areas
[32]. RM approach finally can rebalance the neuronal motor activity
increased in FMS patients by emotional distress.
RM is efficaciously rapid and safe, because easy to be tailored and
respectful of pain threshold, extremely low in FMS patients.
The feasibility of a rehabilitation treatment should guarantee a high
adherence to the program and reduce the probability of dropouts. In
our study, differently from other MBT, applied in FMS, the adherence
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to RM program is complete. Thus, it could be an useful rehabilitative
tool in FMS patients, also as a “first step intervention” when other
techniques are difficult to be used [4,43].
In the management of FMS patients, MBT, and in particular RM, in
order to maintain a long-term effect, should be used at regular cycles
and integrated, in a multicomponent approach, with medical treatment
and educational measures.
Another recent study of ours [8] assessed the efficacy of 'Body
movement and perception' a method that integrates RM with low
impact exercises derived from soft gymnastics. The results showed an
improvement of many symptoms of FMS (pain, fatigue, irritability,
well-being, quality of movement, postural self-control, ability to relax
mind and body, movement perception and tender point scores); this
method is useful when performed after RM treatment in patients
unable to deal with standard training programs.
Our study has some limitations, such as the low number of the
patients and the absence of a control group and follows up.
Further investigations on wider cohorts of patients and with
longitudinal design are required to confirm the utility of IHT as a
diagnostic and grading tool in order to design tailored interventions
for FMS patients.
Conclusion
In conclusion, we confirm in FMS patients the prevalence of NMH,
assessed by IHT, and the efficacy of RM. This latter is an important non
pharmacological treatment, useful not only in improving FMS
symptoms, but also in reducing NMH, that could be considered as
another therapeutic target in FMS.
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